International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

Keating, 2007, Surveillance testing among survivors of early-stage breast cancer, J Clin Oncol, 25, 1074, 10.1200/JCO.2006.08.6876 2007, Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force, Breast (Edinburgh, Scotland), 16, 9, 10.1016/j.breast.2006.11.002 Cardoso, 2009, International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy, J Natl Cancer Inst, 101, 1174, 10.1093/jnci/djp235 Pagani, 2010, International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?, J Natl Cancer Inst, 102, 456, 10.1093/jnci/djq029 de Bock, 2004, Patient's needs and preferences in routine follow-up after treatment for breast cancer, Br J Cancer, 90, 1144, 10.1038/sj.bjc.6601655 Loprinzi, 2003, Doc, shouldn't we be getting some tests?, J Clin Oncol, 21, 108s, 10.1200/JCO.2003.01.190 Muss, 1991, Perceptions of follow-up care in women with breast cancer, Am J Clin Oncol, 14, 55, 10.1097/00000421-199102000-00013 Hillner, 1997, Measuring standards of care for early breast cancer in an insured population, J Clin Oncol, 15, 1401, 10.1200/JCO.1997.15.4.1401 Simon, 1996, An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer, Breast Cancer Res Treat, 37, 39, 10.1007/BF01806630 Grunfeld, 2010, Population-based longitudinal study of follow-up care for breast cancer survivors, J Oncol Pract/Am Soc Clin Oncol, 6, 174, 10.1200/JOP.200009 Mille, 2000, Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center, J Clin Oncol, 18, 1718, 10.1200/JCO.2000.18.8.1718 Kokko, 2005, Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial, Breast Cancer Res Treat, 93, 255, 10.1007/s10549-005-5199-2 Mapelli, 1995, Economic evaluation of diagnostic follow-up after primary treatment for breast cancer. Results of the Working Group on Economic-Organizational Aspects of Follow-up, Ann Oncol, 6, 61, 10.1093/annonc/6.suppl_2.S61 Simon, 1996, Clinical surveillance for early stage breast cancer: an analysis of claims data, Breast Cancer Res Treat, 40, 119, 10.1007/BF01806207 Kroenke, 2005, Weight, weight gain, and survival after breast cancer diagnosis, J Clin Oncol, 23, 1370, 10.1200/JCO.2005.01.079 Pierce, 2007, Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial, J Am Med Assoc, 298, 289, 10.1001/jama.298.3.289 Obedian, 2000, Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy, J Clin Oncol, 18, 2406, 10.1200/JCO.2000.18.12.2406 Lu, 2011, The value of routine physical examination in the follow up of women with a history of early breast cancer, Eur J Cancer, 47, 676, 10.1016/j.ejca.2010.11.006 Houssami, 2011, Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer, J Am Med Assoc, 305, 790, 10.1001/jama.2011.188 de Bock, 2004, Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review, J Clin Oncol, 22, 4010, 10.1200/JCO.2004.06.080 Lu, 2009, Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis, Breast Cancer Res Treat, 114, 403, 10.1007/s10549-008-0023-4 Montgomery, 2007, Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature, Br J Cancer, 97, 1632, 10.1038/sj.bjc.6604065 van der Sangen, 2012, Detection of local recurrence following breast-conserving treatment in young women with early breast cancer: optimization of long-term follow-up strategies, Breast (Edinburgh, Scotland) Lu, 2009, The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer, Eur J Cancer, 45, 3000, 10.1016/j.ejca.2009.08.007 Saslow, 2007, American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography, CA Cancer J Clin, 57, 75, 10.3322/canjclin.57.2.75 Rosselli Del Turco, 1994, Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up, J Am Med Assoc, 271, 1593, 10.1001/jama.271.20.1593 Palli, 1999, Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer follow-up, J Am Med Assoc, 281, 1586, 10.1001/jama.281.17.1586 GIVIO, 1994, Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators, J Am Med Assoc, 271, 1587, 10.1001/jama.1994.03510440047031 Rojas, 2005, Follow-up strategies for women treated for early breast cancer, Cochrane Database Syst Rev (Online) Rutgers, 1989, Follow-up after treatment of primary breast cancer, Br J Surg, 76, 187, 10.1002/bjs.1800760227 Pandya, 1985, A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report, Cancer, 55, 202, 10.1002/1097-0142(19850101)55:1<202::AID-CNCR2820550132>3.0.CO;2-X Joseph, 1998, Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer, Ann Surg Oncol, 5, 522, 10.1007/BF02303645 Lumachi, 1999, Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3, Anticancer Res, 19, 4485 Brenner, 2003, Cancer risks attributable to low doses of ionizing radiation: assessing what we really know, Proc Natl Acad Sci U S A, 100, 13761, 10.1073/pnas.2235592100 Brenner, 2004, Estimated radiation risks potentially associated with full-body CT screening, Radiology, 232, 735, 10.1148/radiol.2323031095 Kokko, 2002, Ca 15-3 in the follow-up of localised breast cancer: a prospective study, Eur J Cancer, 38, 1189, 10.1016/S0959-8049(01)00429-4 Chan, 1997, Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease, J Clin Oncol, 15, 2322, 10.1200/JCO.1997.15.6.2322 Chia, 2007, The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer, Cancer, 110, 973, 10.1002/cncr.22867 Khatcheressian, 2006, American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting, J Clin Oncol, 24, 5091, 10.1200/JCO.2006.08.8575 Kataja, 2009, Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann Oncol, 20, 10, 10.1093/annonc/mdp114 Hillner, 2003, American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, J Clin Oncol, 21, 4042, 10.1200/JCO.2003.08.017 2013 Schnipper, 2012, American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology, J Clin Oncol, 30, 1715, 10.1200/JCO.2012.42.8375 Giordano, 2004, Is breast cancer survival improving?, Cancer, 100, 44, 10.1002/cncr.11859 Cardoso, 2010, Clinical practice guidelines: locally recurrent or metastatic breast cancer: ESMO clinical practice guidlines for diagnosis, treatment, and follow-up, Ann Oncol, 21, 15, 10.1093/annonc/mdq160 Thomssen, 2011, AGO Recommendations for diagnosis and treatment of patients with primary and metastatic breast cancer, Update 2011. Breast Care (Basel), 6, 299 Harris, 2007, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200/JCO.2007.14.2364 Cardoso, 2012, 1st International consensus guidelines for advanced breast cancer (ABC 1), Breast (Edinburgh, Scotland), 21, 242, 10.1016/j.breast.2012.03.003 Khasraw, 2011, The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?, Curr Oncol Rep, 13, 17, 10.1007/s11912-010-0137-9 Thompson, 2010, Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS), Breast Cancer Res, 12, R92, 10.1186/bcr2771 Andersson, 1999, Eur J Cancer, 35, 39, 10.1016/S0959-8049(98)00354-2 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Drotman, 2001, Breast cancer: assessing the use of routine pelvic CT in patient evaluation, Am J Roentgenol, 176, 1433, 10.2214/ajr.176.6.1761433 Constantinidou, 2011, Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital, Ann Oncol, 22, 307, 10.1093/annonc/mdq343 Auguste, 2011, An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence, Health Technol Assess (Winchester, England), 15, iii Mahner, 2008, Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-d-glucose, conventional imaging and computed tomography for staging of breast cancer, Ann Oncol, 19, 1249, 10.1093/annonc/mdn057 Dehdashti, 2009, PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer, Breast Cancer Res Treat, 113, 509, 10.1007/s10549-008-9953-0 Ellis, 2009, Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study, J Am Med Assoc, 302, 774, 10.1001/jama.2009.1204 Forero-Torres, 2010, Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer, Clin Breast Cancer, 10, 275, 10.3816/CBC.2010.n.035 Shie, 2008, Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer, Clin Nucl Med, 33, 97, 10.1097/RLU.0b013e31815f23b7 Costelloe, 2009, Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis, Lancet Oncol, 10, 606, 10.1016/S1470-2045(09)70088-9 De Giorgi, 2010, 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer, J Nucl Med, 51, 1213, 10.2967/jnumed.110.076455 Cristofanilli, 2004, Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N Engl J Med, 351, 781, 10.1056/NEJMoa040766 Pierga, 2012, High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients, Ann Oncol, 23, 618, 10.1093/annonc/mdr263 Liu, 2009, Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer, J Clin Oncol, 27, 5153, 10.1200/JCO.2008.20.6664 Hartkopf, 2011, Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer, Anticancer Res, 31, 979 Gradilone, 2011, Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization, Ann Oncol, 22, 86, 10.1093/annonc/mdq323 Flores, 2010, Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer, Br J Cancer, 102, 1495, 10.1038/sj.bjc.6605676 Sieuwerts, 2011, mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients, Clin Cancer Res, 17, 3600, 10.1158/1078-0432.CCR-11-0255 Munzone, 2010, Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer, Clin Breast Cancer, 10, 392, 10.3816/CBC.2010.n.052 Mayer, 2010, Living with metastatic breast cancer: a global patient survey, Community Oncol, 7, 406, 10.1016/S1548-5315(11)70415-6